Kinematic assay of plasma glucose concentration without blood sampling
AssigneeBlue Marble Research, Inc.
InventorJung J. Lee
Life of this patent
Estimating the term…
Abstract
A method is described which can identify the plasma glucose optical signal from the high background in a "total finger spectrum" by causing changes in the signal upon altering glucose concentration by administering a glucose-specific drug such as insulin, and also determine the original concentration by measuring the rate of the change as a first order kinetic dependent on the initial concentration.
Claims13
A method for the determination of an in vivo glucose concentration without blood sampling comprising the steps of:
- (a) directing a beam of light to a body part of a patient;
- (b) administering a hypoglycemic drug to the patient to impose a kinematic perturbation in the in vivo glucose concentration;
- (c) identifying an optical absorption band of in vivo glucose measuring an intensity of a glucose signal;
- (d) measuring a rate of decrease of the intensity of the glucose signal with time;
- (e) determining an original glucose signal from the rate of decrease measured and
- (f) converting the original signal into an original in glucose concentration.
A method for identifying instrumental signals associated with in situ cellular components and measuring in vivo a concentration of the components comprising the steps of:
- (a) administering to a patient a compound specific for the component to be measured, wherein the compound imposes a kinematic perturbation which changes the in vivo concentration of the component specific for the component to be measured;
- (b) measuring a rate of change of the in vivo concentration of the component;
- (c) and determining the original in vivo concentration of the component from the rate of change measured.
A method for determining in vivo glucose concentrations without blood sampling comprising the steps of:
- (a) detecting an intensity of glucose signals non invasively by projecting energy through a body part of a patient and detecting energy received through the body part;
- (b) administering a hypoglycemic drug to the patient
- (c) sequentially detecting changes in the intensity of the glucose signals;
- (d) measuring a rate of changing intensity of the sequentially detected glucose signals;
- and
- (e) determining an original glucose concentration from the measured rate of changing intensity.
A method for the determination of in vivo glucose concentrations without blood sampling comprising the steps of:
- (a) administering a hypoglycemic drug to a patient;
- (b) projecting light through a body part of the patient, measuring a decreasing optical spectrum at subsequent time intervals to obtain difference spectra, and identifying a peak absorbance position of the in vivo glucose from the difference spectra corresponding to the decreasing glucose concentration;
- (c) plotting changing peak absorbances on a logarithmic axis versus time on a linear abscissa (semi-log plot) to obtain a straight line;
- (d) interpolating the straight line with a negative slope to the axis logarithmic at time zero for obtaining an original pure glucose absorbance;
- (e) comparing the original glucose absorbance against a reference table comprising a column of original glucose absorbance values matched with pre-determined blood glucose concentrations determined by a blood sampling method before administration of the hypoglycemic drug;
- (f) and determining the original glucose concentration from the comparing step.
A method for identifying instrumental signals in in-vivo cellular components and measuring an in vivo concentration of the components comprising the steps of:
- (a) administering a compound to a patient specific for a component to be measured that causes changes in the in vivo concentration of the component;
- (b) projecting energy through a body part of the patient and detecting energy received through the body part to measure differential changes in intensity of a spectrum over a time period to obtain an identity of a peak position of the component;
- (c) plotting the changes in intensity of the peak position on an appropriate scale in a semi-log plot to obtain a line;
- (d) interpolating the obtained line to an original intensity at a time before the administering of the compound to obtain an original pure component intensity;
- (e) matching the so obtained original pure component intensity against a reference table constructed by collection of data obtained by measuring concentration through blood sampling before administration of the compound.
A method for determining in vivo glucose concentrations comprising the steps of:
- (a) identifying a glucose signal by administration of a hypoglycemic drug, finding a changing intensity signal and interpreting the changing intensity signal as a decreasing glucose signal;
- (b) obtaining a first order kinetic analysis of the decreasing glucose signal to obtain a kinetic constant from a slope of a semi-log plot for storing in a database for a diagnostic purpose.
A method for identifying in vivo glucose signals blood sampling comprising the steps of:
- (a) administering a hypoglycemic drug to a patient;
- (b) obtaining with respect to a time a changing glucose signal to identify a pure glucose spectrum and its peak intensity;
- (c) plotting the changing peak intensity on an appropriate plot in a first order or semi-log kinetic plot;
- (d) interpolating a straight line to an origin at time zero to obtain an original in vivo blood plasma glucose concentration.
Dependencies are inferred from the claim text.